Embla Genomics ApS: Financial statements 2025
CVR: 41685603
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Embla Genomics ApS (CVR 41685603) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 14,722 and a net result of DKK 7,398 compared with DKK -7,604 the year before. Equity in the 2025 report amounted to DKK 49,675. The solvency ratio was 71.1%.
- Gross Profit
- DKK 14,722
- Profit/Loss
- DKK 7,398
- Equity
- DKK 49,675
- Total Assets
- DKK 69,821
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 15K | 7K | 50K | 0 |
| 2024 | - | -8K | -8K | 42K | 0 |
| 2023 | - | -9K | -11K | 50K | 0 |
| 2022 | - | -10K | -8K | 60K | 0 |
Official annual report
How creditworthy is Embla Genomics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of September 25, 2025, Albert Helmut Werner has stepped down as director of Embla Genomics ApS.
Embla Genomics ApS has published its annual report for 2024. Gross profit came to DKK -8,262, and the net result was DKK -7,604.
About Embla Genomics ApS
Embla Genomics ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company has been dissolved on 19 October 2026. The company was registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company has 2 employees (2021). In 2025, the company reported a gross profit of DKK 14,722 and a net result of DKK 7,398 compared with DKK -7,604 the year before. Equity in the 2025 report amounted to DKK 49,675.